Foà, Robin <br/><br/>
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.  [electronic resource] 

 -  Blood  Dec 2011 
 - 6521-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-05-351403  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antigens, CD--metabolism<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Dasatinib<br/>Drug Administration Schedule<br/>Female<br/>Flow Cytometry<br/>Fusion Proteins, bcr-abl--genetics<br/>Gene Expression Regulation, Leukemic--drug effects<br/>Humans<br/>Immunophenotyping<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--administration & dosage<br/>Recurrence<br/>Remission Induction<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Steroids--administration & dosage<br/>Thiazoles--administration & dosage<br/>Time Factors<br/>Treatment Outcome<br/>Young Adult